It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
One of the critical events that regulates muscle cell differentiation is the replacement of the lamin B receptor (LBR)-tether with the lamin A/C (LMNA)-tether to remodel transcription and induce differentiation-specific genes. Here, we report that localization and activity of the LBR-tether are crucially dependent on the muscle-specific chaperone HSPB3 and that depletion of HSPB3 prevents muscle cell differentiation. We further show that HSPB3 binds to LBR in the nucleoplasm and maintains it in a dynamic state, thus promoting the transcription of myogenic genes, including the genes to remodel the extracellular matrix. Remarkably, HSPB3 overexpression alone is sufficient to induce the differentiation of two human muscle cell lines, LHCNM2 cells, and rhabdomyosarcoma cells. We also show that mutant R116P-HSPB3 from a myopathy patient with chromatin alterations and muscle fiber disorganization, forms nuclear aggregates that immobilize LBR. We find that R116P-HSPB3 is unable to induce myoblast differentiation and instead activates the unfolded protein response. We propose that HSPB3 is a specialized chaperone engaged in muscle cell differentiation and that dysfunctional HSPB3 causes neuromuscular disease by deregulating LBR.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details










1 University of Modena and Reggio Emilia, Centre for Neuroscience and Nanotechnology, Department of Biomedical, Metabolic and Neural Sciences, Modena, Italy (GRID:grid.7548.e) (ISNI:0000000121697570)
2 Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany (GRID:grid.429509.3) (ISNI:0000 0004 0491 4256)
3 Bambino Gesù Children’s Hospital, IRCCS, Department of Oncohematology, Rome, Italy (GRID:grid.414125.7) (ISNI:0000 0001 0727 6809)
4 Sapienza University of Rome, Department of Biology and Biotechnologies “Charles Darwin”, Rome, Italy (GRID:grid.7841.a)
5 Sapienza University of Rome, Department of Biology and Biotechnologies “Charles Darwin”, Rome, Italy (GRID:grid.7841.a); Fondazione Istituto Italiano di Tecnologia (IIT), Center for Life Nano- & Neuro-Science, Rome, Italy (GRID:grid.7841.a)
6 University of Bologna, IRCCS St. Orsola Hospital, Department of Biomedical and Neuromotor Sciences DIBINEM, University of Bologna, Bologna, Italy; Centre for Applied Biomedical Research - CRBA, Bologna, Italy (GRID:grid.6292.f) (ISNI:0000 0004 1757 1758)
7 Sorbonne Université, Inserm, Institut de Myologie, Centre de Recherche en Myologie, Paris, France (GRID:grid.418250.a) (ISNI:0000 0001 0308 8843)
8 Max Planck Institute of Molecular Cell Biology and Genetics, Dresden, Germany (GRID:grid.419537.d) (ISNI:0000 0001 2113 4567); Dewpoint Therapeutics GmbH, Dresden, Germany (GRID:grid.419537.d)
9 Ben-Gurion University of the Negev, Department of Clinical Biochemistry and Pharmacology and the National Institute for Biotechnology in the Negev, Beer Sheva, Israel (GRID:grid.7489.2) (ISNI:0000 0004 1937 0511)
10 Technische Universität Dresden, Biotechnology Center (BIOTEC), Center for Molecular and Cellular Bioengineering (CMCB), Dresden, Germany (GRID:grid.4488.0) (ISNI:0000 0001 2111 7257)
11 Ben-Gurion University of the Negev, Department of Life Sciences, Beer Sheva, Israel (GRID:grid.7489.2) (ISNI:0000 0004 1937 0511)
12 Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany (GRID:grid.429509.3) (ISNI:0000 0004 0491 4256); University of Cambridge, Medical Research Council (MRC), Cambridge, UK (GRID:grid.5335.0) (ISNI:0000000121885934)